scholarly journals The Nature of Immune Responses to Influenza Vaccination in High-Risk Populations

Viruses ◽  
2021 ◽  
Vol 13 (6) ◽  
pp. 1109
Author(s):  
Kristin B. Wiggins ◽  
Maria A. Smith ◽  
Stacey Schultz-Cherry
Keyword(s):  
High Risk ◽  
Immune Responses ◽  
Influenza Vaccination ◽  
Influenza A ◽  
The Elderly ◽  
H1n1 Influenza ◽  
Influenza Vaccines ◽  
High Risk Populations ◽  
2009 H1n1 ◽  
Seasonal Epidemics

The current pandemic has brought a renewed appreciation for the critical importance of vaccines for the promotion of both individual and public health. Influenza vaccines have been our primary tool for infection control to prevent seasonal epidemics and pandemics such as the 2009 H1N1 influenza A virus pandemic. Certain high-risk populations, including the elderly, people with obesity, and individuals with comorbidities such as type 2 diabetes mellitus, are more susceptible to increased disease severity and decreased vaccine efficacy. High-risk populations have unique microenvironments and immune responses that contribute to increased vulnerability for influenza infections. This review focuses on these differences as we investigate the variations in immune responses to influenza vaccination. In order to develop better influenza vaccines, it is critical to understand how to improve responses in our ever-growing high-risk populations.

scholarly journals “World in motion” – emulsion adjuvants rising to meet the pandemic challenges

npj Vaccines ◽  
2021 ◽  
Vol 6 (1) ◽  
Author(s):  
Derek T. O’Hagan ◽  
Robbert van der Most ◽  
Rushit N. Lodaya ◽  
Margherita Coccia ◽  
Giuseppe Lofano
Keyword(s):  
Immune Responses ◽  
Plasma Cells ◽  
Influenza Pandemic ◽  
H1n1 Influenza ◽  
T Cell Response ◽  
Influenza Vaccines ◽  
Vaccine Adjuvants ◽  
Immunological Responses ◽  
2009 H1n1 ◽  
Human Immunity

AbstractEmulsion adjuvants such as MF59 and AS03 have been used for more than two decades as key components of licensed vaccines, with over 100 million doses administered to diverse populations in more than 30 countries. Substantial clinical experience of effectiveness and a well-established safety profile, along with the ease of manufacturing have established emulsion adjuvants as one of the leading platforms for the development of pandemic vaccines. Emulsion adjuvants allow for antigen dose sparing, more rapid immune responses, and enhanced quality and quantity of adaptive immune responses. The mechanisms of enhancement of immune responses are well defined and typically characterized by the creation of an “immunocompetent environment” at the site of injection, followed by the induction of strong and long-lasting germinal center responses in the draining lymph nodes. As a result, emulsion adjuvants induce distinct immunological responses, with a mixed Th1/Th2 T cell response, long-lived plasma cells, an expanded repertoire of memory B cells, and high titers of cross-neutralizing polyfunctional antibodies against viral variants. Because of these various properties, emulsion adjuvants were included in pandemic influenza vaccines deployed during the 2009 H1N1 influenza pandemic, are still included in seasonal influenza vaccines, and are currently at the forefront of the development of vaccines against emerging SARS-CoV-2 pandemic variants. Here, we comprehensively review emulsion adjuvants, discuss their mechanism of action, and highlight their profile as a benchmark for the development of additional vaccine adjuvants and as a valuable tool to allow further investigations of the general principles of human immunity.

scholarly journals Humoral and Cell-Mediated Immune Responses to Monovalent 2009 Influenza A/H1N1 and Seasonal Trivalent Influenza Vaccines in High-Risk Children

2012 ◽  
Vol 160 (1) ◽  
pp. 74-81 ◽  
Author(s):  
Caroline B. Long ◽  
Irene Ramos ◽  
Deepa Rastogi ◽  
Deepa Manwani ◽  
Ginger Janow ◽  
...  
Keyword(s):  
High Risk ◽  
Immune Responses ◽  
Influenza A ◽  
Influenza Vaccines ◽  
Influenza A H1n1 ◽  
High Risk Children

scholarly journals Intersection of Sex and Frailty in Humoral Immune Responses to Influenza Vaccine in Community-Dwelling Older Adults

2020 ◽  
Vol 4 (Supplement_1) ◽  
pp. 271-272
Author(s):  
Janna Shapiro ◽  
Helen Kuo ◽  
Rosemary Morgan ◽  
Huifen Li ◽  
Sabra Klein ◽  
...  
Keyword(s):  
Older Adults ◽  
Immune Responses ◽  
Influenza A ◽  
Community Dwelling ◽  
Influenza Vaccines ◽  
Health Study ◽  
Cardiovascular Health Study ◽  
High Dose ◽  
Humoral Immune ◽  
Humoral Immune Responses

Abstract Older adults bear the highest burden of severe disease and complications associated with seasonal influenza, with annual vaccination serving as the best option for protection. Variability in vaccine efficacy exists, yet the host factors that affect immune responses to inactivated influenza vaccines (IIV) are incompletely understood. We hypothesized that sex and frailty interact to affect vaccine-induced humoral responses among older adults. To test this hypothesis, community-dwelling adults above 75 years of age were recruited yearly, assessed for frailty (as defined by the Cardiovascular Health Study criteria), and vaccinated with the high-dose trivalent IIV. Humoral immune responses were evaluated via hemagglutination inhibition titers. The study began during the 2014-2015 influenza season, with yearly cohorts ranging from 76-163 individuals. A total of 617 vaccinations were delivered from 2014-2019. In preliminary analyses, the outcome of interest was seroconversion, defined as ≥ 4-fold rise in titers. Crude odds ratios suggest that females are more likely to seroconvert to influenza A strains (H1N1: OR = 1.39, (0.98-1.96) ; H3N2: 1.17 (0.85 – 1.62)), while males are more likely to seroconvert to the B strain (OR = 0.85 (0.60 – 1.22)). Furthermore, this sex difference was modified by frailty – for example, the odds of seroconversion to H1N1 were 65% higher for females than males among those who were nonfrail, and only 30% higher among females who were frail. Together, these results suggest that sex and frailty interact to impact immune responses to influenza vaccines. These findings may be leveraged to better protect vulnerable populations.

Epidemiological analysis of critically ill adult patients with pandemic influenza A(H1N1) in South Korea

2012 ◽  
Vol 141 (5) ◽  
pp. 1070-1079 ◽  
Author(s):  
S. B. HONG ◽  
E. Y. CHOI ◽  
S. H. KIM ◽  
G. Y. SUH ◽  
M. S. PARK ◽  
...  
Keyword(s):  
South Korea ◽  
Influenza A ◽  
Multivariate Logistic Regression Analysis ◽  
H1n1 Influenza ◽  
Epidemiological Analysis ◽  
Influenza A H1n1 ◽  
Failure Assessment ◽  
2009 H1n1 ◽  
Independent Risk Factors ◽  
Chronic Comorbidities

SUMMARYA total of 245 patients with confirmed 2009 H1N1 influenza were admitted to the intensive-care units of 28 hospitals (South Korea). Their mean age was 55·3 years with 68·6% aged >50 years, and 54·7% male. Nine were obese and three were pregnant. One or more comorbidities were present in 83·7%, and nosocomial acquisition occurred in 14·3%. In total, 107 (43·7%) patients received corticosteroids and 66·1% required mechanical ventilation. Eighty (32·7%) patients died within 30 days after onset of symptoms and 99 (40·4%) within 90 days. Multivariate logistic regression analysis showed that the clinician's decision to prescribe corticosteroids, older age, Sequential Organ Failure Assessment score and nosocomial bacterial pneumonia were independent risk factors for 90-day mortality. In contrast with Western countries, critical illness in Korea in relation to 2009 H1N1 was most common in older patients with chronic comorbidities; nosocomial acquisition occurred occasionally but disease in obese or pregnant patients was uncommon.

scholarly journals Subcutaneous Immunization with Baculovirus Surface-Displayed Hemagglutinin of Pandemic H1N1 Influenza A Virus Induces Protective Immunity in Mice

2011 ◽  
Vol 18 (9) ◽  
pp. 1582-1585 ◽  
Author(s):  
Mookkan Prabakaran ◽  
Tao Meng ◽  
Fang He ◽  
Tan YunRui ◽  
Jia Qiang ◽  
...  
Keyword(s):  
Virus Infection ◽  
Protective Immunity ◽  
Influenza A ◽  
H1n1 Virus ◽  
H1n1 Influenza ◽  
Influenza Virus Hemagglutinin ◽  
Inactive Form ◽  
2009 H1n1 ◽  
Subcutaneous Immunization ◽  
H1n1 Virus Infection

ABSTRACTThe protective immunity of baculovirus displaying influenza virus hemagglutinin (BacHA) against influenza 2009 H1N1 virus infection in a murine model was investigated. The results showed that mice vaccinated with live BacHA or an inactive form of adjuvanted BacHA had enhanced specific antibody responses and induced protective immunity against 2009 H1N1 virus infection, suggesting the potential of baculovirus as a live or inactivated vaccine.

scholarly journals Cross-Neutralizing Antibodies to Pandemic 2009 H1N1 and Recent Seasonal H1N1 Influenza A Strains Influenced by a Mutation in Hemagglutinin Subunit 2

2011 ◽  
Vol 7 (6) ◽  
pp. e1002081 ◽  
Author(s):  
Wei Wang ◽  
Christine M. Anderson ◽  
Christopher J. De Feo ◽  
Min Zhuang ◽  
Hong Yang ◽  
...  
Keyword(s):  
Neutralizing Antibodies ◽  
Influenza A ◽  
H1n1 Influenza ◽  
2009 H1n1

scholarly journals A new common mutation in the hemagglutinin of the 2009 (H1N1) influenza A virus

PLoS Currents ◽  
2010 ◽  
Vol 2 ◽  
pp. RRN1162 ◽  
Author(s):  
Sebastian Maurer-Stroh ◽  
Raphael Tze Chuen Lee ◽  
Frank Eisenhaber ◽  
Lin Cui ◽  
Shiau Pheng Phuah ◽  
...  
Keyword(s):  
Influenza A Virus ◽  
Influenza A ◽  
H1n1 Influenza ◽  
Common Mutation ◽  
2009 H1n1

scholarly journals Impaired memory B-cell recall responses in the elderly following recurrent influenza vaccination

PLoS ONE ◽  
2021 ◽  
Vol 16 (8) ◽  
pp. e0254421
Author(s):  
Rodrigo B. Abreu ◽  
Greg A. Kirchenbaum ◽  
Giuseppe A. Sautto ◽  
Emily F. Clutter ◽  
Ted M. Ross
Keyword(s):  
Influenza Virus ◽  
High Risk ◽  
Antibody Response ◽  
B Cell ◽  
Influenza A ◽  
The Elderly ◽  
World Health ◽  
Memory B Cell ◽  
Virus Vaccination ◽  
Health Organization

Influenza is a highly contagious viral respiratory disease that affects million of people worldwide each year. Annual vaccination is recommended by the World Health Organization with the goal of reducing influenza severity and limiting transmission through elicitation of antibodies targeting the hemagglutinin (HA) glycoprotein. The antibody response elicited by current seasonal influenza virus vaccines is predominantly strain-specific, but pre-existing influenza virus immunity can greatly impact the serological antibody response to vaccination. However, it remains unclear how B cell memory is shaped by recurrent annual vaccination over the course of multiple seasons, especially in high-risk elderly populations. Here, we systematically profiled the B cell response in young adult (18–34 year old) and elderly (65+ year old) vaccine recipients that received annual split inactivated influenza virus vaccination for 3 consecutive seasons. Specifically, the antibody serological and memory B-cell compartments were profiled for reactivity against current and historical influenza A virus strains. Moreover, multiparametric analysis and antibody landscape profiling revealed a transient increase in strain-specific antibodies in the elderly, but with an impaired recall response of pre-existing memory B-cells, plasmablast (PB) differentiation and long-lasting serological changes. This study thoroughly profiles and compares the immune response to recurrent influenza virus vaccination in young and elderly participants unveiling the pitfalls of current influenza virus vaccines in high-risk populations.

Lower cellular immune responses to influenza A (H3N2) in the elderly

2009 ◽  
Vol 81 (8) ◽  
pp. 1471-1476 ◽  
Author(s):  
Na Jia ◽  
Chris Li ◽  
Yun-Xi Liu ◽  
Jan H. Richardus ◽  
Dan Feng ◽  
...  
Keyword(s):  
Immune Responses ◽  
Influenza A ◽  
The Elderly ◽  
Cellular Immune Responses ◽  
Cellular Immune
Sign in / Sign up

Export Citation Format

Share Document